
AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

